Mobile

A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group, phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor ag...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-001469-16

A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group, phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a thrombopoietin receptor agonist, SB-497115-GR, when administered as 30, 50, and 75 mg once daily for 12 weeks in subjects with chronic hepatitis C–related thrombocytopenia who are potential candidates for antiviral treatment with pegylated interferon and ribavirin

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

1. To evaluate the effects of SB-497115-GR on platelet counts when administered once daily for 4 weeks (Part 1) to subjects with chronic hepatitis C-related thrombocytopenia, prior to receiving antiviral therapy.

Critère d'inclusion

  • Thrombocytopenia caused by hepatitis-C

Liens